In Veritas Medical Diagnostics, Inc. (IVME) ist ein börsennotiertes Unternehmen im Finanzdienstleistungen Sektor, tätig in der Shell Companies Branche. Der Hauptsitz des Unternehmens ist in Inverness, United Kingdom. Der aktuelle CEO ist G. T. Cooper.
IVME hat IPO-Datum 2004-07-14, 7 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $60.23K.
In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.
